Page 1 of 145
(IgNS) Ig Certified Pharmacist (IgCP) Credential Practice
Exam Actual Test Questions and Correct Answers With
Rationales LATEST THIS YEAR
EXAM COVERAGE (Point Form)
• Provider: Immunoglobulin National Society (IgNS)
• Credential: Ig Certified Pharmacist (IgCP)
• Eligibility: Current, active, unrestricted Registered Pharmacist (RPh) license in the US or Canada
• Recertification: Every 3 years; 1,000 hours of infusion therapy experience within past 2 years; 40
recertification units (20 from IgNS National Conference)
Core Domains
1. Ig Therapy Formulation: Product types (IVIG, SCIG, fSCIG), manufacturing processes
(solvent/detergent treatment, nanofiltration, pasteurization), stabilizers (sucrose, maltose,
glycine, proline), storage and handling
2. Pathophysiology & Clinical Use: Primary immunodeficiencies (CVID, XLA, SAD),
autoimmune/neurologic conditions (CIDP, ITP, GBS, Kawasaki disease), immunomodulation vs.
replacement therapy
3. Patient Management: Dose calculation (weight-based), infusion rate management, switching
between IVIG and SCIG (bioavailability adjustment), trough level monitoring (target 500-600
mg/dL for PID)
4. Safety & Adverse Events: Infusion reactions (headache, nausea, flushing), anaphylaxis
management (ABCs, epinephrine), FDA black box warnings (thrombotic events, renal
dysfunction), hemolysis monitoring, aseptic meningitis
5. Advocacy & Collaboration: Interdisciplinary team coordination, patient education, formulary
management, appropriate utilization
Key Reference Information
• FDA Black Box Warnings: Thrombotic events and renal dysfunction
• Sucrose-stabilized IVIG products: Highest risk of osmotic nephropathy
• Solvent/detergent treatment: Inactivates enveloped viruses (HIV, Hepatitis B, Hepatitis C)
• SCIG bioavailability: Approximately 66% of IVIG
• Typical IVIG dosing for PID: 200-600 mg/kg every 3-4 weeks
• Target trough IgG level for PID: 5-6 g/L (500-600 mg/dL)
• IVIG half-life: Approximately 20-45 days depending on product and patient factors
, Page 2 of 145
1. A 62-year-old male with common variable immunodeficiency (CVID) has been on a stable dose of
intravenous immunoglobulin (IVIG) 10% for two years. During his last two infusions, he developed a
moderate headache and nausea towards the end of the infusion. What is the most appropriate initial
modification to his infusion plan for the next visit?
A) Pre-medicate with oral acetaminophen and diphenhydramine
B) Switch to a product with a different stabilizer
C) Reduce the total calculated dose by 20%
D) Add 100 mg of intravenous hydrocortisone to the IVIG bag
Answer: A) Pre-medicate with oral acetaminophen and diphenhydramine
Rationale: Pre-medication with acetaminophen and an antihistamine is a first-line strategy to mitigate
common, mild to moderate infusion-related reactions like headache and nausea. This intervention
addresses the symptoms without altering the effective dose or unnecessarily changing the product .
2. Which of the following patient characteristics is most critical to assess prior to initiating IVIG
therapy to mitigate the risk of acute renal failure?
A) History of migraine headaches
B) Presence of selective IgA deficiency
, Page 3 of 145
C) Baseline renal function and diabetes mellitus status
D) Recent travel history
Answer: C) Baseline renal function and diabetes mellitus status
Rationale: Patients with pre-existing renal impairment, diabetes mellitus, or volume depletion are at
higher risk for osmotic nephropathy, particularly with sucrose-stabilized IVIG products. Assessing
baseline renal function is essential for risk stratification and product selection .
3. According to the FDA black box warning for IVIG products, which two serious adverse events
require particular vigilance?
A) Hemolysis and Hepatitis C transmission
B) Anaphylaxis and febrile reactions
C) Thrombotic events and renal dysfunction
D) Aseptic meningitis and eczema
Answer: C) Thrombotic events and renal dysfunction
Rationale: The FDA-mandated black box warning for IVIG highlights the risks of thrombotic events and
acute renal dysfunction. Pharmacists must screen patients for risk factors and ensure adequate
hydration to mitigate these potentially life-threatening complications .
, Page 4 of 145
4. A patient with a history of severe IgA deficiency (undetectable serum IgA and known anti-IgA
antibodies) requires immunoglobulin therapy. Which product characteristic is most important for
safety?
A) High concentration (20%) for subcutaneous administration
B) A product formulated with maltose as a stabilizer
C) An IgA-depleted product to minimize the risk of anaphylaxis
D) A lyophilized product that requires reconstitution
Answer: C) An IgA-depleted product to minimize the risk of anaphylaxis
Rationale: Patients with anti-IgA antibodies are at risk for severe anaphylactic reactions upon exposure
to IgA. Selecting an IgA-depleted immunoglobulin product significantly reduces this risk .
5. Which of the following conditions is typically treated with HIGH-DOSE immunomodulatory IVIG
rather than low-dose replacement therapy?
A) Common Variable Immunodeficiency (CVID)
B) X-linked Agammaglobulinemia (XLA)
C) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
D) Specific antibody deficiency (SAD)
(IgNS) Ig Certified Pharmacist (IgCP) Credential Practice
Exam Actual Test Questions and Correct Answers With
Rationales LATEST THIS YEAR
EXAM COVERAGE (Point Form)
• Provider: Immunoglobulin National Society (IgNS)
• Credential: Ig Certified Pharmacist (IgCP)
• Eligibility: Current, active, unrestricted Registered Pharmacist (RPh) license in the US or Canada
• Recertification: Every 3 years; 1,000 hours of infusion therapy experience within past 2 years; 40
recertification units (20 from IgNS National Conference)
Core Domains
1. Ig Therapy Formulation: Product types (IVIG, SCIG, fSCIG), manufacturing processes
(solvent/detergent treatment, nanofiltration, pasteurization), stabilizers (sucrose, maltose,
glycine, proline), storage and handling
2. Pathophysiology & Clinical Use: Primary immunodeficiencies (CVID, XLA, SAD),
autoimmune/neurologic conditions (CIDP, ITP, GBS, Kawasaki disease), immunomodulation vs.
replacement therapy
3. Patient Management: Dose calculation (weight-based), infusion rate management, switching
between IVIG and SCIG (bioavailability adjustment), trough level monitoring (target 500-600
mg/dL for PID)
4. Safety & Adverse Events: Infusion reactions (headache, nausea, flushing), anaphylaxis
management (ABCs, epinephrine), FDA black box warnings (thrombotic events, renal
dysfunction), hemolysis monitoring, aseptic meningitis
5. Advocacy & Collaboration: Interdisciplinary team coordination, patient education, formulary
management, appropriate utilization
Key Reference Information
• FDA Black Box Warnings: Thrombotic events and renal dysfunction
• Sucrose-stabilized IVIG products: Highest risk of osmotic nephropathy
• Solvent/detergent treatment: Inactivates enveloped viruses (HIV, Hepatitis B, Hepatitis C)
• SCIG bioavailability: Approximately 66% of IVIG
• Typical IVIG dosing for PID: 200-600 mg/kg every 3-4 weeks
• Target trough IgG level for PID: 5-6 g/L (500-600 mg/dL)
• IVIG half-life: Approximately 20-45 days depending on product and patient factors
, Page 2 of 145
1. A 62-year-old male with common variable immunodeficiency (CVID) has been on a stable dose of
intravenous immunoglobulin (IVIG) 10% for two years. During his last two infusions, he developed a
moderate headache and nausea towards the end of the infusion. What is the most appropriate initial
modification to his infusion plan for the next visit?
A) Pre-medicate with oral acetaminophen and diphenhydramine
B) Switch to a product with a different stabilizer
C) Reduce the total calculated dose by 20%
D) Add 100 mg of intravenous hydrocortisone to the IVIG bag
Answer: A) Pre-medicate with oral acetaminophen and diphenhydramine
Rationale: Pre-medication with acetaminophen and an antihistamine is a first-line strategy to mitigate
common, mild to moderate infusion-related reactions like headache and nausea. This intervention
addresses the symptoms without altering the effective dose or unnecessarily changing the product .
2. Which of the following patient characteristics is most critical to assess prior to initiating IVIG
therapy to mitigate the risk of acute renal failure?
A) History of migraine headaches
B) Presence of selective IgA deficiency
, Page 3 of 145
C) Baseline renal function and diabetes mellitus status
D) Recent travel history
Answer: C) Baseline renal function and diabetes mellitus status
Rationale: Patients with pre-existing renal impairment, diabetes mellitus, or volume depletion are at
higher risk for osmotic nephropathy, particularly with sucrose-stabilized IVIG products. Assessing
baseline renal function is essential for risk stratification and product selection .
3. According to the FDA black box warning for IVIG products, which two serious adverse events
require particular vigilance?
A) Hemolysis and Hepatitis C transmission
B) Anaphylaxis and febrile reactions
C) Thrombotic events and renal dysfunction
D) Aseptic meningitis and eczema
Answer: C) Thrombotic events and renal dysfunction
Rationale: The FDA-mandated black box warning for IVIG highlights the risks of thrombotic events and
acute renal dysfunction. Pharmacists must screen patients for risk factors and ensure adequate
hydration to mitigate these potentially life-threatening complications .
, Page 4 of 145
4. A patient with a history of severe IgA deficiency (undetectable serum IgA and known anti-IgA
antibodies) requires immunoglobulin therapy. Which product characteristic is most important for
safety?
A) High concentration (20%) for subcutaneous administration
B) A product formulated with maltose as a stabilizer
C) An IgA-depleted product to minimize the risk of anaphylaxis
D) A lyophilized product that requires reconstitution
Answer: C) An IgA-depleted product to minimize the risk of anaphylaxis
Rationale: Patients with anti-IgA antibodies are at risk for severe anaphylactic reactions upon exposure
to IgA. Selecting an IgA-depleted immunoglobulin product significantly reduces this risk .
5. Which of the following conditions is typically treated with HIGH-DOSE immunomodulatory IVIG
rather than low-dose replacement therapy?
A) Common Variable Immunodeficiency (CVID)
B) X-linked Agammaglobulinemia (XLA)
C) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
D) Specific antibody deficiency (SAD)
